However, in the B16-OVA tumor model, we demonstrated that when the B16-OVA tumor was grafted, the immune response against the OVA CD4 epitope was also increased when mice were immunized with constructs fused with oligoDOMTM, contributing to the overall reduction in tumor growth rate. Here, CD4 is linked to neoplasm.